

# Leah A Comment

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4387640/publications.pdf>

Version: 2024-02-01

8  
papers

182  
citations

1937685  
4  
h-index

1720034  
7  
g-index

8  
all docs

8  
docs citations

8  
times ranked

248  
citing authors

#	ARTICLE	IF	CITATIONS
1	Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response. <i>Cancer Discovery</i> , 2021, 11, 282-292.	9.4	132
2	The use of external control data for predictions and futility interim analyses in clinical trials. <i>Neuro-Oncology</i> , 2022, 24, 247-256.	1.2	29
3	Association and interplay of surgeon and hospital volume with mortality after open abdominal aortic aneurysm repair in the modern era. <i>Journal of Vascular Surgery</i> , 2021, 73, 1593-1602.e7.	1.1	6
4	Association of <i>CD274</i> (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2022, 27, 732-739.	3.7	5
5	Evidence-Based Development and Clinical Use of Precision Oncology Therapeutics. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 440-443.	4.7	4
6	Abstract 864: Changes over time in real-world next-generation sequencing (NGS) test use in patients (pts) with advanced non-small cell lung cancer (aNSCLC). <i>Cancer Research</i> , 2021, 81, 864-864.	0.9	4
7	Bayesian data fusion: Probabilistic sensitivity analysis for unmeasured confounding using informative priors based on secondary data. <i>Biometrics</i> , 2022, 78, 730-741.	1.4	2
8	Real-world overall survival (OS) and time to therapy discontinuation (TTD) of patients (pts) with mCRPC treated with second-generation novel hormonal therapies (NHT) associated with tissue-based comprehensive genomic profiling (CGP).. <i>Journal of Clinical Oncology</i> , 2021, 39, 142-142.	1.6	0